Current stock price

Investor Relations

GCANRx is a publicly traded biotechnology company led by an experienced team of executives and scientists. The company is focused on the the development and commercialization of innovative Cannabinoid delivery systems.

February 27, 2019

The Greater Cannabis Company Announces Uplisting To New Market Tier

January 07, 2019

The Greater Cannabis Company Announces Distribution Agreement With Leading Global Cannabis Company iCAN: Israel Cannabis Ltd.

October 31, 2018

The Greater Cannabis Company to Update Shareholders on Corporate Strategy and Developments of Eluting . . .

Corporate Presentation

See our latest corporate presentation.

Stock Information

See our current stock performance.

Aitan Zacharin

Aitan Zacharin

CEO, Director

Mark Radom

Mark Radom

VP, General Counsel

David Tavor

David Tavor

Director, Board of Directors

Hock S. Tan

Hock S. Tan, PhD

Chairman, Scientific Advisory Board

More about our management

SEC Filings

February 15, 2019

Current Report

February 14, 2019

Registration of securities [Section 12(g)]

January 23, 2019

Initial Statement of Beneficial Ownership of Securities

November 19, 2018

Quarterly Report

FAQ

What is the ticker symbol for GCANRx?

Shares of GCANRx are traded on the OTC Markets under the ticker symbol GCAN.


Where is GCANRx’s corporate headquarters?

GCANRx is based out of Baltimore, MD.


When does GCANRx’s fiscal year end?

December 31.


Who is GCANRx’s transfer agent?

Pacific Stock Transfer. 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119. (800) 785-7782. info@pacificstocktransfer.com


Who is GCANRx’s auditor?

Michael T. Studer CPA P.C. 111 West Sunrise Highway, Second Floor East Freeport, NY 11520, United State


What is GCANRx's CUSIP number?

391657103


What is GCANRx's CIK Number?

0001695473


What is GCANRx's SIC and Classification?

2834; Pharmaceutical Preparations


What is GCANRx's O/S and Float?

As of October 26, 2018 the outstanding shares are 30,846,492 and the float is approximately 13,426,759

Sign up for email alerts

Stay up to date on the latest news.